www.fdanews.com/articles/126794-boston-scientific-suffers-losses-due-to-shipment-hold-on-icds
Boston Scientific Suffers Losses Due to Shipment Hold on ICDs
May 5, 2010
A month-long shipment hold on implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators is expected to cost Boston
Scientific $300 million this year. The company reported last week that it had lost $72 million in the first quarter alone due to the hold. However, Boston
Scientific expects to benefit from a projected 3 percent to 5 percent growth in the global cardiac rhythm device market.
Devices & Diagnostics Letter
Devices & Diagnostics Letter